Multiple sclerosis (Houndmills, Basingstoke, England) · 2026
B-cell repopulation and postpartum MS disease activity following ofatumumab cessation for pregnancy in women with multiple sclerosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bongol Denisse, Antoniou Maria, Chataway Jeremy, Ciccarelli Olga, Khaleeli Zhaleh, Swanton Josephine, Toosy Ahmed, Wilson Heather, Chung Karen, Brownlee Wallace
Аннотация
BACKGROUND: Data on ofatumumab use in women with multiple sclerosis (WwMS) planning pregnancy are limited.
OBJECTIVES: We conducted an observational study in WwMS to describe third-trimester CD19 counts, postpartum MS activity and pregnancy outcomes after pausing ofatumumab at conception.
RESULTS: Twenty-five women were included. Third-trimester CD19 counts remained depleted (median 0.017 × 109/L) in 23 available results. No postpartum relapses occurred (25/25 [100%]), and majority (22/25 [88%]) had no new magnetic resonance imaging (MRI) activity. No new safety signals were identified.
CONCLUSIONS: B-cell depletion persisted into the third trimester following ofatumumab cessation for pregnancy with low postpartum MS activity, although limited by small sample.
OBJECTIVES: We conducted an observational study in WwMS to describe third-trimester CD19 counts, postpartum MS activity and pregnancy outcomes after pausing ofatumumab at conception.
RESULTS: Twenty-five women were included. Third-trimester CD19 counts remained depleted (median 0.017 × 109/L) in 23 available results. No postpartum relapses occurred (25/25 [100%]), and majority (22/25 [88%]) had no new magnetic resonance imaging (MRI) activity. No new safety signals were identified.
CONCLUSIONS: B-cell depletion persisted into the third trimester following ofatumumab cessation for pregnancy with low postpartum MS activity, although limited by small sample.